Research aims to improve effectiveness of radiotherapy treatment for prostate cancer

January 30, 2012

A new three year research project aimed at improving the effectiveness of radiotherapy treatment for men affected by prostate cancer is taking place at Queen's.

With new and improved treatments needed for men with advanced prostate cancer, it is hoped the project will identify a new approach using radiotherapy, a commonly used treatment, to treat the disease more effectively.

Funded by a £99,273 PhD research grant awarded by The Prostate Cancer Charity, the project will first seek to understand how a man's prostate cancer becomes resistant to radiotherapy. Following this, the researchers will test a combination of existing drug treatments alongside radiotherapy to overcome this resistance. It is hoped that the cancer will become more sensitive to radiotherapy and thereby improve the success of the treatment to stop the disease in its tracks.

Lead researcher at Queen's University Belfast's Centre for Cancer Research and Cell Biology, Professor of Radiation Biology Kevin Prise, said: "The use of radiotherapy to treat prostate cancer is currently restricted by the cancer's ability to develop resistance to the treatment. Drugs exist which can help to 'sensitise' the cancer cells to radiotherapy, and in this study we will use these drugs in combination with radiotherapy to try and improve the success of prostate cancer treatment, using techniques that are already available."

The grant has been awarded, as part of The Prostate Cancer Charity's ongoing programme of investment in research to help tackle this disease. This year, the Charity has awarded over £2 million - its largest research investment to date - to institutions across the UK to improve the diagnosis and treatment of prostate cancer.

Dr Kate Holmes, Research Manager at The Prostate Cancer Charity said: "Radiotherapy has been used for a number of years to treat prostate cancer. In some cases, however, the tumour develops resistance and does not respond well to this treatment. We hope that this new research will be able to improve the success of radiotherapy, so that it can be used to kill more cancer cells and further delay the spread of the disease. We are looking forward to working closely with the team and eagerly await the results of the study."
For further information contact the Communications Office. Tel: 028-90-97-3087 or email

Queen's University Belfast

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to